Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BC2059 + GNE-049 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BC2059 | BC-2059|BC 2059|Tegatrabetan|Tegavivint | CTNNB1 Inhibitor 27 | Tegavivint (BC2059) binds to beta-catenin (CTNNB1) and interferes with binding to TBL1 and TBLR1, resulting in increased degradation of beta-catenin and potentially leading to increased apoptosis of tumor cells with activated canonical Wnt signaling (PMID: 28500235, PMID: 30793158). | |
GNE-049 | CBP/p300 inhibitor 13 | GNE-049 inhibits the CBP and p300 bromodomains, resulting in decreased coactivator activity, and potentially leading to decreased tumor growth (PMID: 28819026). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|